Achieving protection against HBV in HIV patients: Finding the best strategy

References

• Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009; 49:S138-45; PMID:19399813; http://dx.doi.org/10.1002/hep.22883
   PubMed Web of Science ®Google Scholar
• Vargas JI, Jensen D, Sarmiento V, Peirano F, Acuna P, Fuster F, Soto S, Ahumada R, Huilcaman M, Bruna M, et al. Presence of anti-HBc is associated to high rates of HBV resolved infection and low threshold for Occult HBV Infection in HIV patients with negative HBsAg in Chile. J Med Virol 2016; 88:639-46; PMID:26381185; http://dx.doi.org/10.1002/jmv.24384
   PubMed Web of Science ®Google Scholar
• Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K,Vella S, Kirk O, Lundgren JD, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. Aids 2005; 19:593-601; PMID:15802978; http://dx.doi.org/10.1097/01.aids.0000163936.99401.fe
   PubMed Web of Science ®Google Scholar
• Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Muñoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). The Lancet 2002; 360:1921-26; PMID:12493258; http://dx.doi.org/10.1016/S0140-6736(02)11913-1
   PubMed Web of Science ®Google Scholar
• Chun HM, Roediger MP, Hullsiek KH, Thio CL, Agan BK, Bradley WP, Peel SA, Jagodzinski LL, Weintrob AC, Ganesan A, et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis 2012; 205:185-93; PMID:22147794; http://dx.doi.org/10.1093/infdis/jir720
   PubMed Web of Science ®Google Scholar
• CDC. Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedules for Persons Aged 0 Through 18 Years and Adults Aged 19 Years and Older — United States, 2013. MMWR 2013; 62:1; PMID:23364301
   PubMed Web of Science ®Google Scholar
• Wilkins E, Nelson M, Agarwal K, Awoyemi D, Barnes E, Bhagani S, Brook G, Brown A, Castelino S, Cooke G, et al. British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Med 2013; 14(Suppl 4):1-71; PMID:24581304; http://dx.doi.org/10.1111/hiv.12106
   PubMed Web of Science ®Google Scholar
• Ryom L, Boesecke C, Gisler V, Manzardo C, Rockstroh JK, Puoti M, Furrer H, Miro JM, Gatell JM, Pozniak A et al. Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons. HIV Med 2016; 17:83-88; PMID:26548563; http://dx.doi.org/10.1111/hiv.12322
   Google Scholar
• Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis 2012; 12:966-76; PMID:23174382; http://dx.doi.org/10.1016/S1473-3099(12)70243-8
   PubMed Web of Science ®Google Scholar
• Fuster F, Vargas JI, Jensen D, Sarmiento V, Acuna P, Peirano F, Fuster F, Arab JP, Martínez F. CD4/CD8 ratio as a predictor of the response to HBV vaccination in HIV-positive patients: A prospective cohort study. Vaccine 2016; 34:1889-95; PMID:26945101; http://dx.doi.org/10.1016/j.vaccine.2016.02.055
   PubMed Web of Science ®Google Scholar
• Launay O. Safety and Immunogenicity of 4 Intramuscular Double Doses and 4 Intradermal Low Doses vs Standard Hepatitis B Vaccine Regimen in Adults With HIV-1 A Randomized Controlled Trial. JAMA 2011; 305:1432-40; PMID:21486976; http://dx.doi.org/10.1001/jama.2011.351
   PubMed Web of Science ®Google Scholar
• Chaiklang K, Wipasa J, Chaiwarith R, Praparattanapan J, Supparatpinyo K. Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial. PLoS One 2013; 8:e80409; PMID:24265819; http://dx.doi.org/10.1371/journal.pone.0080409
   PubMed Web of Science ®Google Scholar
• Launay O, Rosenberg AR, Rey D, Pouget N, Michel ML, Reynes J, Neau D, Raffi F, Piroth L, Carrat F. Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1: Secondary Analysis of a Randomized Clinical Trial. JAMA Intern Med 2016; 176:603-10; PMID:27064975; http://dx.doi.org/10.1001/jamainternmed.2016.0741
   PubMed Web of Science ®Google Scholar
• Bruce MG, Bruden D, Hurlburt D, Zanis C, Thompson G, Rea L, Toomey M, Townshend-Bulson L, Rudolph K, Bulkow L, et al. Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose. J Infect Dis 2016; 214:16-22; PMID:26802139; http://dx.doi.org/10.1093/infdis/jiv748
   PubMed Web of Science ®Google Scholar
• Sticchi L, Bruzzone B, Caligiuri P, Rappazzo E, Lo Casto M, De Hoffer L, Gustinetti G, Viscoli C, Di Biagio A. Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients. Hum Vaccin Immunother 2015; 11:263-9; PMID:25483544; http://dx.doi.org/10.4161/hv.36162
   PubMed Web of Science ®Google Scholar
• Lao-Araya M, Puthanakit T, Aurpibul L, Taecharoenkul S, Sirisanthana T, Sirisanthana V. Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy. Vaccine 2011; 29:3977-81; PMID:21473954; http://dx.doi.org/10.1016/j.vaccine.2011.03.077
   PubMed Web of Science ®Google Scholar
• Rey D, Piroth L, Wendling M-J, Miailhes P, Michel M-L, Dufour C, Haour G, Sogni P, Rohel A, Ajana F, et al. Safety and immunogenicity of double-dose vs. standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis 2015; 15:1283-91; PMID:26257021; http://dx.doi.org/10.1016/S1473-3099(15)00220-0
   PubMed Web of Science ®Google Scholar